Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study

Colorectal Cancer Screening IMPATTO study working group

Research output: Contribution to journalArticle

Abstract

To evaluate the impact of faecal immunochemical test (FIT) screening on stage distribution at diagnosis, and to estimate relative incidence rates by stage in screened at first and subsequent rounds vs. unscreened. We included all incident cases occurring in 2000–2008 in 50- to 71-year-olds residing in areas with an FIT-screening programme. Multinomial logistic models were computed to estimate the relative risk ratio (RRR) of stages I and IV, compared to stage II + III, adjusting for age, sex, geographical area, and incidence year. Proportions were then used to estimate incidence rate ratios (IRR) by stage for screened subjects at the first and at subsequent rounds vs. unscreened subjects, applying the expected changes in overall incidence during screening phases. 11,663 cancers were included: 5965 in not-invited and 5,698 in invited subjects, 3,425 of whom attendees. Compared to not-invited, invited subjects had RRR 2.04 (95% CI: 1.84; 2.46) of stage I and RRR 0.77 (95% CI: 0.69; 0.87) of stage IV. Differences were stronger comparing attendees vs. nonattendees. Interval cancers were more frequently stage I compared to non-invited (RRR 1.54; 95% CI: 1.15; 2.04), but there was no difference for stage IV. IRRs in screened at first round vs. unscreened were 4.6 (95% CI: 4.2; 5.1), 1.4 (95% CI: 1.3; 1.5) and 0.7 (95% CI: 0.6; 0.9) for stages I, II + III and IV, respectively; in the following rounds the IRRs of screened vs. unscreened were 1.4 (95% CI: 1.2; 1.6), 0.8 (95% CI: 0.7; 0.9) and 0.3 (95% CI: 0.1; 0.4) for stages I, II + III and IV, respectively. FIT screening reduces the incidence of metastatic cancers by about 70% after the first round.

Original languageEnglish
JournalInternational Journal of Cancer
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Colorectal Neoplasms
Odds Ratio
Incidence
Neoplasms
Logistic Models
insulin receptor-related receptor

Keywords

  • cancer registries
  • colonoscopy
  • colorectal cancer screening
  • epidemiology
  • Faecal immunochemical test

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer : Results from the IMPATTO study. / Colorectal Cancer Screening IMPATTO study working group.

In: International Journal of Cancer, 01.01.2019.

Research output: Contribution to journalArticle

@article{73749889c81845e18f6a4372161e6198,
title = "Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study",
abstract = "To evaluate the impact of faecal immunochemical test (FIT) screening on stage distribution at diagnosis, and to estimate relative incidence rates by stage in screened at first and subsequent rounds vs. unscreened. We included all incident cases occurring in 2000–2008 in 50- to 71-year-olds residing in areas with an FIT-screening programme. Multinomial logistic models were computed to estimate the relative risk ratio (RRR) of stages I and IV, compared to stage II + III, adjusting for age, sex, geographical area, and incidence year. Proportions were then used to estimate incidence rate ratios (IRR) by stage for screened subjects at the first and at subsequent rounds vs. unscreened subjects, applying the expected changes in overall incidence during screening phases. 11,663 cancers were included: 5965 in not-invited and 5,698 in invited subjects, 3,425 of whom attendees. Compared to not-invited, invited subjects had RRR 2.04 (95{\%} CI: 1.84; 2.46) of stage I and RRR 0.77 (95{\%} CI: 0.69; 0.87) of stage IV. Differences were stronger comparing attendees vs. nonattendees. Interval cancers were more frequently stage I compared to non-invited (RRR 1.54; 95{\%} CI: 1.15; 2.04), but there was no difference for stage IV. IRRs in screened at first round vs. unscreened were 4.6 (95{\%} CI: 4.2; 5.1), 1.4 (95{\%} CI: 1.3; 1.5) and 0.7 (95{\%} CI: 0.6; 0.9) for stages I, II + III and IV, respectively; in the following rounds the IRRs of screened vs. unscreened were 1.4 (95{\%} CI: 1.2; 1.6), 0.8 (95{\%} CI: 0.7; 0.9) and 0.3 (95{\%} CI: 0.1; 0.4) for stages I, II + III and IV, respectively. FIT screening reduces the incidence of metastatic cancers by about 70{\%} after the first round.",
keywords = "cancer registries, colonoscopy, colorectal cancer screening, epidemiology, Faecal immunochemical test",
author = "{Colorectal Cancer Screening IMPATTO study working group} and Massimo Vicentini and Manuel Zorzi and Emanuela Bovo and Pamela Mancuso and Marco Zappa and Gianfranco Manneschi and Lucia Mangone and {Giorgi Rossi}, Paolo",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ijc.32089",
language = "English",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer

T2 - Results from the IMPATTO study

AU - Colorectal Cancer Screening IMPATTO study working group

AU - Vicentini, Massimo

AU - Zorzi, Manuel

AU - Bovo, Emanuela

AU - Mancuso, Pamela

AU - Zappa, Marco

AU - Manneschi, Gianfranco

AU - Mangone, Lucia

AU - Giorgi Rossi, Paolo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - To evaluate the impact of faecal immunochemical test (FIT) screening on stage distribution at diagnosis, and to estimate relative incidence rates by stage in screened at first and subsequent rounds vs. unscreened. We included all incident cases occurring in 2000–2008 in 50- to 71-year-olds residing in areas with an FIT-screening programme. Multinomial logistic models were computed to estimate the relative risk ratio (RRR) of stages I and IV, compared to stage II + III, adjusting for age, sex, geographical area, and incidence year. Proportions were then used to estimate incidence rate ratios (IRR) by stage for screened subjects at the first and at subsequent rounds vs. unscreened subjects, applying the expected changes in overall incidence during screening phases. 11,663 cancers were included: 5965 in not-invited and 5,698 in invited subjects, 3,425 of whom attendees. Compared to not-invited, invited subjects had RRR 2.04 (95% CI: 1.84; 2.46) of stage I and RRR 0.77 (95% CI: 0.69; 0.87) of stage IV. Differences were stronger comparing attendees vs. nonattendees. Interval cancers were more frequently stage I compared to non-invited (RRR 1.54; 95% CI: 1.15; 2.04), but there was no difference for stage IV. IRRs in screened at first round vs. unscreened were 4.6 (95% CI: 4.2; 5.1), 1.4 (95% CI: 1.3; 1.5) and 0.7 (95% CI: 0.6; 0.9) for stages I, II + III and IV, respectively; in the following rounds the IRRs of screened vs. unscreened were 1.4 (95% CI: 1.2; 1.6), 0.8 (95% CI: 0.7; 0.9) and 0.3 (95% CI: 0.1; 0.4) for stages I, II + III and IV, respectively. FIT screening reduces the incidence of metastatic cancers by about 70% after the first round.

AB - To evaluate the impact of faecal immunochemical test (FIT) screening on stage distribution at diagnosis, and to estimate relative incidence rates by stage in screened at first and subsequent rounds vs. unscreened. We included all incident cases occurring in 2000–2008 in 50- to 71-year-olds residing in areas with an FIT-screening programme. Multinomial logistic models were computed to estimate the relative risk ratio (RRR) of stages I and IV, compared to stage II + III, adjusting for age, sex, geographical area, and incidence year. Proportions were then used to estimate incidence rate ratios (IRR) by stage for screened subjects at the first and at subsequent rounds vs. unscreened subjects, applying the expected changes in overall incidence during screening phases. 11,663 cancers were included: 5965 in not-invited and 5,698 in invited subjects, 3,425 of whom attendees. Compared to not-invited, invited subjects had RRR 2.04 (95% CI: 1.84; 2.46) of stage I and RRR 0.77 (95% CI: 0.69; 0.87) of stage IV. Differences were stronger comparing attendees vs. nonattendees. Interval cancers were more frequently stage I compared to non-invited (RRR 1.54; 95% CI: 1.15; 2.04), but there was no difference for stage IV. IRRs in screened at first round vs. unscreened were 4.6 (95% CI: 4.2; 5.1), 1.4 (95% CI: 1.3; 1.5) and 0.7 (95% CI: 0.6; 0.9) for stages I, II + III and IV, respectively; in the following rounds the IRRs of screened vs. unscreened were 1.4 (95% CI: 1.2; 1.6), 0.8 (95% CI: 0.7; 0.9) and 0.3 (95% CI: 0.1; 0.4) for stages I, II + III and IV, respectively. FIT screening reduces the incidence of metastatic cancers by about 70% after the first round.

KW - cancer registries

KW - colonoscopy

KW - colorectal cancer screening

KW - epidemiology

KW - Faecal immunochemical test

UR - http://www.scopus.com/inward/record.url?scp=85060625223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060625223&partnerID=8YFLogxK

U2 - 10.1002/ijc.32089

DO - 10.1002/ijc.32089

M3 - Article

AN - SCOPUS:85060625223

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

ER -